CONMED (CNMD) Q3 2026 Earnings Call Transcript
CONMED (CNMD) reported Q3 2026 net revenue of $335.6M, with organic growth of 6.7% YoY. Adjusted EPS was $1.04, exceeding expectations. AirSeal and Buffalo Filter drove sales growth, with AirSeal showing strong performance in robotic and laparoscopic surgery. The company remains optimistic about long-term growth prospects for these products.
How this was made
The 30-second read
Why it matters
The earnings release adds fresh quantitative data for valuation models and may influence short‑term price action.
Market read
Primary relevance to CNMD shareholders; secondary relevance to med‑tech sector and competitors.
What to watch
Potential upside from new AirSeal indication and upcoming regulatory approvals not reflected in current numbers.
Background
Conmed (CNMD) presented its Q3 2026 earnings call, highlighting revenue, EPS, product updates, and strategic initiatives.
Ticker impact
Q3 2026 earnings call disclosed net revenue of $335.6M and adjusted EPS of $1.04, the first public release of these figures.
likely limited upside pressure as results meet guidance, but no major catalyst for a sharp move
First report of earnings provides fresh data; market reaction expected to be muted given modest scale.
Market effects
Provides a data point for the medical device sector, especially surgical equipment manufacturers.
Limited to US and international markets where Conmed sells its products.
Low global impact; primarily relevant to investors in small‑cap med‑tech stocks.
Counterpoint
Despite earnings beat, the modest revenue growth and narrow product focus could limit upside.
Key entities
- CompanyConmed
Medical device manufacturer reporting Q3 2026 results.
- CompanyIntuitive Surgical
Partner in AirSeal robotic indication.
